Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Results of Operations and Financial Condition
Item 2.02
On March 22, 2019, Neuralstem, Inc. (the “Company”) reported its financial results for the year ended December 31, 2018. The press release is attached as Exhibit99.01 and is incorporated herein by reference.
The information furnished under Items 2.02, including the accompanying Exhibit 99.01 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any subsequent filing by the Company under the Securities Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
|
Exhibit No. |
Description |
| 99.01 | Press Release Dated March 22, 2019 |
Neuralstem, Inc. Exhibit
EX-99.01 2 exh_9901.htm EXHIBIT 99.01 EdgarFiling EXHIBIT 99.01 Neuralstem Reports Year End 2018 Fiscal Results GERMANTOWN,…
To view the full exhibit click here
About Neuralstem, Inc. (NASDAQ:CUR)
Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.
